The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials.
 
Ana Ortega-Franco
No Relationships to Disclose
 
Emma Darlington
No Relationships to Disclose
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics; Boehringer Ingelheim
Research Funding - Athenex (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Repare Therapeutics (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
(OPTIONAL) Uncompensated Relationships - Roche
 
Donna M. Graham
Consulting or Advisory Role - Clinigen Group
Speakers' Bureau - Cancer Drug Development Forum
Research Funding - Pfizer (Inst)
 
Fiona Thistlethwaite
Honoraria - Bayer
Consulting or Advisory Role - Bristol-Myers Squibb; Enara Bio; GlaxoSmithKline; Immatics; Ixaka; Janssen; Pfizer (Inst); T-Knife; Zelluna
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Ixaka
Other Relationship - iMatch
 
Patricia Roxburgh
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune (Inst); Athenex (Inst); Bayer (Inst); Clovis Oncology (Inst); Forma Therapeutics (Inst); Immutep (Inst); Iovance Biotherapeutics (Inst); Starpharma (Inst); Tesaro/GSK
Research Funding - AstraZeneca Canada (Inst); Tesaro (Inst)
 
Robin Joseph Young
No Relationships to Disclose
 
Stefan N. Symeonides
Consulting or Advisory Role - Bicycle Therapeutics (Inst); Boxer Capital (Inst); Bristol-Myers Squibb (Inst); Duke Street Bio (Inst); Eisai (Inst); Ellipses Pharma (Inst); EUSA Pharma (Inst); MedAnnex (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Vaccitech (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Ipsen (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Roche/Genentech (Inst); Sapience Therapeutics (Inst); Sierra Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - BioNTech; Bristol-Myers Squibb; Ipsen; MSD
 
Bristi Basu
Consulting or Advisory Role - Eisai (Inst); GenMab (Inst); Roche (Inst)
Speakers' Bureau - Eisai Europe; Eisai Europe (Inst)
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Roche
 
Fiona J. Collinson
Research Funding - Bristol-Myers Squibb
 
Victoria Coyle
Honoraria - Gilead Sciences (I)
Consulting or Advisory Role - SERVIER
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); CellCentric (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Daniel H. Palmer
Consulting or Advisory Role - AstraZeneca; BMS (Inst); Boston Scientific; Eisai; MSD; Roche; Sirtex Medical; Viatris
Research Funding - AstraZeneca; Bayer; BMS; Nucana; Sirtex Medical
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Julie Stevenson
No Relationships to Disclose
 
Paul O’Regan
No Relationships to Disclose
 
George Burghel
No Relationships to Disclose
 
Amy Henshaw
No Relationships to Disclose
 
Alastair Greystoke
Consulting or Advisory Role - AstraZeneca; BMSi; Boehringer Ingelheim; Janssen; Lilly; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Foundation Medicine; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen
Speakers' Bureau - Janssen; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep